Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 2358-2363

  Kanhai, Danny A ^a   Visseren, Frank L J ^a   Van Der Graaf, Yolanda ^a   Schoneveld, Arjan H ^a,b   Catanzariti, Louise M ^a   Timmers, Leo ^a   Kappelle, L Jaap ^c   Uiterwaal, Cuno S P M ^a   Lim, Sai Kiang ^d   Sze, Siu Kwan ^e   Pasterkamp, Gerard ^a   De Kleijn, Dominique P V ^a,b,f  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^f NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Epidemiology; Microvesicles; Mortality; Proteins; Vascular events

Indexed keywords

CD14 ANTIGEN; CYSTATIN C; MEMBRANE PROTEIN; SERINE PROTEINASE INHIBITOR; SERPIN F2; SERPIN G1; UNCLASSIFIED DRUG; SERPIN-2;

ADULT; ALL CAUSE MORTALITY; ARTICLE; BRAIN ISCHEMIA; CELLULAR DISTRIBUTION; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE VESICLE; MICROVESICLE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE; VASCULAR MORTALITY; BLOOD; CAUSE OF DEATH; ELECTRON MICROSCOPY; EPIDEMIOLOGY; INCIDENCE; METABOLISM; MIDDLE AGED; NETHERLANDS; PATHOLOGY; SURVIVAL RATE; TRENDS; ULTRASTRUCTURE; VASCULAR DISEASES;

CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; RISK FACTORS; SERPINS; SURVIVAL RATE; VASCULAR DISEASES;

EID: 84885615128     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.231     Document Type: Article

References (40)

1. E. Cocucci, G. Racchetti, and J. Meldolesi Shedding microvesicles: artefacts no more Trends Cell Biol 19 2009 43 51
2. E.J. van der Vlist, E.N. Nolte-'t Hoen, W. Stoorvogel, G.J. Arkesteijn, and M.H. Wauben Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and qualitative analysis by high-resolution flow cytometry Nat Protoc 7 2012 1311 1326
3. W. Jy, L.L. Horstman, and J.J. Jimenez Measuring circulating cell-derived microparticles J Thromb Haemost 2 2004 1842 1851
4. O. Morel, N. Morel, and B. Hugel The significanceof circulating microparticles in physiology, inflammatory and thrombotic diseases Rev Med Interne 26 2005 791 801
5. M.C. Martinez, S. Tual-Chalot, D. Leonetti, and R. Andriantsitohaina Microparticles: targets and tools in cardiovascular disease Trends Pharmacol Sci 32 2011 659 665
6. P.E. Rautou, A.C. Vion, and N. Amabile Microparticles, vascular function, and atherothrombosis Circ Res 109 2011 593 606
7. A. Aharon, T. Tamari, and B. Brenner Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells Thromb Haemost 100 2008 878 885
8. P. Wolf The nature and significance of platelet products inhuman plasma Br J Haematol 13 1967 269 288
9. G. Hron, M. Kollars, and H. Weber Tissue factor-positive microparticles:cellular origin and association with coagulation activation in patients with colorectal cancer Thromb Haemost 97 2007 119 123
10. D.D. Taylor, and C. Gercel-Taylor MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer Gynecol Oncol 110 2008 13 21
11. M. Davila, A. Amirkhosravi, and E. Coll Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation J Thromb Haemost 6 2008 1517 1524
12. M. Mack, A. Kleinschmidt, and H. Brühl Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection Nat Med 6 2000 769 775
13. T. Rozmyslowicz, M. Majka, and J. Kijowski Platelet-and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV AIDS 17 2003 33 42
14. B. Fevrier, D. Vilette, and F. Archer Cells release prions in association with exosomes Proc Natl Acad Sci U S A 101 2004 9683 9688
15. C. Robertson, S.A. Booth, D.R. Beniac, M.B. Coulthart, T.F. Booth, and A. McNicol Cellular prion protein is released on exosomes from activated platelets Blood 107 2006 3907 3911
16. F. Sabatier, P. Darmon, and B. Hugel Type 1 and type 2 diabetic patients display different patterns of cellular microparticles Diabetes 51 2002 2840 2845
17. Z. Mallat, H. Benamer, and B. Hugel Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes Circulation 101 2000 841 843
18. C.M. Boulanger, A. Scoazec, and T. Ebrahimian Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction Circulation 104 2001 2649 2652
19. L. Bernal-Mizrachi, W. Jy, and J.J. Jimenez High levels of circulating endothelial microparticles in patients with acute coronary syndromes Am Heart J 145 2003 962 970
20. C.M. Boulanger, N. Amabile, and A. Tedgui Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease Hypertension 48 2006 180 186
21. T. Nozaki, S. Sugiyama, and K. Sugamura Prognostic value of endothelial microparticles in patients with heart failure Eur J Heart Fail 12 2010 1223 1228
22. L.C. Azevedo, M. Janiszewski, and V. Pontieri Platelet-derived exosomes from septic shock patients induce myocardial dysfunction Crit Care 11 2007 R120
23. W. Yin, B. Ghebrehiwet, and E.I. Peerschke Expression of complement components and inhibitors on platelet microparticles Platelets 19 2008 225 233
24. O.P. Barry, D. Praticò, R.C. Savani, and G.A. FitzGerald Modulation of monocyte-endothelial cell interactions by platelet microparticles J Clin Invest 102 1998 136 144
25. M. Mesri, and D.C. Altieri Endothelial cell activation by leukocyte microparticles J Immunol 161 1998 4382 4387
26. J.M. Sinning, J. Losch, K. Walenta, M. Böhm, G. Nickenig, and N. Werner Circulating CD31 +/Annexin V + microparticles correlate with cardiovascular outcomes Eur Heart J 32 2011 2034 2041
27. P.C. Simons, A. Algra, M.F. van de Laak, D.E. Grobbee, and Y. van der Graaf Second manifestations of ARTerial disease (SMART) study: rationale and design Eur J Epidemiol 15 1999 773 781
28. W. de Jager, H. te Velthuis, B.J. Prakken, W. Kuis, and G.T. Rijkers Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells Clin Diagn Lab Immunol 10 2003 133 139
29. V.R. Dharnidharka, C. Kwon, and G. Stevens Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis Am J Kidney Dis 40 2002 221 226
30. M.G. Shlipak, R. Katz, and M.J. Sarnak Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease Ann Intern Med 145 2006 237 246
31. M.G. Shlipak, M.J. Sarnak, and R. Katz Cystatin C and the risk of death and cardiovascular events among elderly persons N Engl J Med 352 2005 2049 2060
32. A.P. Reiner, E.M. Lange, and N.S. Jenny Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults Arterioscler Thromb Vasc Biol 33 2013 158 164
33. W. Koenig, D. Twardella, H. Brenner, and D. Rothenbacher Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate Clin Chem 51 2005 321 327
34. J. Arpegård, J. Ostergren, U. de Faire, L.O. Hansson, and P. Svensson Cystatin C - a marker of peripheral atherosclerotic disease? Atherosclerosis 199 2008 397 401
35. G.C. Blobe, W.P. Schiemann, and H.F. Lodish Role of transforming growth factor beta in human disease N Engl J Med 342 2000 1350 1358
36. A. Upadhyay, M.G. Larson, and C.Y. Guo Inflammation, kidney function and albuminuria in the Framingham Offspring cohort Nephrol Dial Transplant 26 2011 920 926
37. P. Harrison, and E.M. Cramer Platelet alpha-granules Blood Rev 7 1993 52 62
38. M. Moroi, and N. Aoki Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis J Biol Chem 251 1976 5956 5965
39. A.E. Davis III, P. Mejia, and F. Lu Biological activities of C1 inhibitor Mol Immunol 45 2008 4057 4063
40. T. Palmerini, B.S. Coller, and V. Cervi Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system J Am Coll Cardiol 44 2004 1570 1577